Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 1.00 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.70 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.70 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.70 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrocurcumin SCHEMBL284877 | 1.00 | ALOX5 (1.00) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| Tetrahydrocurcumin SCHEMBL29372158 | 1.00 | ALOX5 (1.00) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL10307533 | 0.95 | ALOX5 (0.91) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL10307817 | 0.95 | ALOX5 (0.91) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL645127 | 0.94 | ALOX5 (0.89) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL10307751 | 0.94 | ALOX5 (0.89) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| Tetrahydrodemethoxycurcumin SCHEMBL29565582 | 0.94 | ALOX5 (0.89) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| Tetrahydrodemethoxycurcumin SCHEMBL4413210 | 0.94 | ALOX5 (0.89) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL28355932 | 0.93 | ALOX5 (0.88) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL10307531 | 0.93 | ALOX5 (0.86) | ALOX5OR51E2CYP3A4CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4512480-A2 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| US-20250017876-A1 | NOVEL TETRAHYDROCURCUMIN COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USING THE SAME | RENIBUS THERAPEUTICS, INC. | 2025-01-16 | — | — | US | claimed |
| EP-3082423-B1 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2024-12-11 | — | — | EP | claimed |
| US-12115138-B2 | Tetrahydrocurcumin compositions, methods of making, and methods of using the same | RENIBUS THERAPEUTICS, INC. (US) | 2024-10-15 | — | — | US | claimed |
| EP-4389225-A2 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2024-06-26 | — | — | EP | claimed |
| EP-3082779-B1 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2023-06-07 | — | — | EP | claimed |
| EP-4062917-A1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2022-09-28 | — | — | EP | claimed |
| EP-3082957-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-04-06 | — | — | EP | claimed |
| EP-3082800-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-02-02 | — | — | EP | claimed |
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12599593-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20220117950-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | BIOMED VALLEY DISCOVERIES, INC. | 2022-04-21 | — | — | US | disclosed |
| EP-3984537-A1 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3082957-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11246859-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3082800-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117950-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | MAP3K1, MAP3K2, MAP3K6 | ALOX5 3768/4885OR51E2 4692/4885CYP3A4 4609/4885 |
| US-12115138-B2 | Tetrahydrocurcumin compositions, methods of making, and methods of using the same | SHH, AHCY, BHMT2 | ALOX5 635/4885OR51E2 4243/4885CYP3A4 1117/4885 |
| US-11246859-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | MAP3K1, MAP3K2, MAP3K6 | ALOX5 3768/4885OR51E2 4692/4885CYP3A4 4609/4885 |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BRAF, SRMS, MAPK3 | ALOX5 2614/4885OR51E2 1236/4885CYP3A4 3855/4885 |
| US-12599593-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | MOK, TTK, MAPK4 | ALOX5 4628/4885OR51E2 2041/4885CYP3A4 2711/4885 |
| US-20250017876-A1 | NOVEL TETRAHYDROCURCUMIN COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USING THE SAME | SHH, AHCY, HMOX1 | ALOX5 738/4885OR51E2 4170/4885CYP3A4 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.